DMAQ vs. NMHI, OLIT, OPTX, ZOOZ, WWAC, CERO, NVNI, BENF, QFTA, and RWOD
Should you be buying Deep Medicine Acquisition stock or one of its competitors? The main competitors of Deep Medicine Acquisition include Nature's Miracle (NMHI), OmniLit Acquisition (OLIT), Syntec Optics (OPTX), ZOOZ Power (ZOOZ), Worldwide Webb Acquisition (WWAC), CERo Therapeutics (CERO), Nvni Group (NVNI), Beneficient (BENF), Quantum FinTech Acquisition (QFTA), and Redwoods Acquisition (RWOD). These companies are all part of the "holding & other investment offices" industry.
Deep Medicine Acquisition (NASDAQ:DMAQ) and Nature's Miracle (NASDAQ:NMHI) are both small-cap unclassified companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations, risk and community ranking.
18.4% of Deep Medicine Acquisition shares are held by institutional investors. Comparatively, 94.6% of Nature's Miracle shares are held by institutional investors. 1.7% of Deep Medicine Acquisition shares are held by insiders. Comparatively, 36.2% of Nature's Miracle shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Nature's Miracle had 3 more articles in the media than Deep Medicine Acquisition. MarketBeat recorded 3 mentions for Nature's Miracle and 0 mentions for Deep Medicine Acquisition. Nature's Miracle's average media sentiment score of 0.64 beat Deep Medicine Acquisition's score of 0.00 indicating that Nature's Miracle is being referred to more favorably in the news media.
Deep Medicine Acquisition and Nature's Miracle both received 0 outperform votes by MarketBeat users.
Deep Medicine Acquisition has a beta of 0.02, meaning that its share price is 98% less volatile than the S&P 500. Comparatively, Nature's Miracle has a beta of -0.6, meaning that its share price is 160% less volatile than the S&P 500.
Summary
Nature's Miracle beats Deep Medicine Acquisition on 5 of the 6 factors compared between the two stocks.
Get Deep Medicine Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for DMAQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DMAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Deep Medicine Acquisition Competitors List
Related Companies and Tools
